Shingles Vaccine and Viagra Show Promise as Alzheimer's Treatments
Three existing drugs, including a shingles vaccine, emerge as top candidates for repurposing against Alzheimer's disease.
Summary
Researchers have identified three existing medications that could be repurposed to fight Alzheimer's disease. After reviewing 80 drugs, an international panel of experts selected a shingles vaccine (Zostavax), Viagra (sildenafil), and riluzole as the most promising candidates. The shingles vaccine emerged as the front-runner, with previous research showing people who received it were 16% less likely to develop dementia. This approach could provide faster, safer, and more affordable treatments than developing new drugs from scratch, which typically takes 10-15 years and costs billions. The selected drugs target biological processes linked to Alzheimer's and have shown encouraging results in laboratory and animal studies.
Detailed Summary
A groundbreaking study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease, potentially offering a faster path to new treatments than developing drugs from scratch. With dementia affecting one million people in the UK and one in three people born today expected to develop it, finding effective treatments is urgent.
Researchers from the University of Exeter led an international panel of 21 dementia specialists who evaluated 80 existing medications. They identified three priority candidates: Zostavax (shingles vaccine), sildenafil (Viagra), and riluzole (motor neurone disease drug). Each targets biological processes linked to Alzheimer's and has shown promising results in laboratory studies.
The shingles vaccine emerged as the strongest candidate. It interacts with the immune system in ways that may counter harmful changes associated with Alzheimer's. Previous research suggests people who received the vaccine were 16% less likely to develop dementia. Viagra may protect nerve cells and reduce tau protein buildup while improving blood flow to the brain. Riluzole has shown cognitive improvements and reduced tau levels in animal studies.
Drug repurposing offers significant advantages over traditional development, which takes 10-15 years and costs billions with no guarantee of success. These medications are already approved and have established safety profiles in older adults. Researchers are now calling for clinical trials to determine whether these drugs truly benefit people with Alzheimer's or those at risk, with plans for a large UK trial of the shingles vaccine.
Key Findings
- Shingles vaccine (Zostavax) reduced dementia risk by 16% in previous studies
- Viagra improved memory and thinking in mouse studies by increasing brain blood flow
- Drug repurposing could provide treatments 10-15 years faster than new drug development
- International expert panel identified 3 priority candidates from 80 existing medications
- All three drugs have established safety profiles and target Alzheimer's-related processes
Methodology
This is a news report summarizing research published in Alzheimer's Research and Therapy. The study involved expert consensus from 21 international dementia specialists reviewing existing literature on 80 medications for repurposing potential.
Study Limitations
The article appears incomplete, cutting off mid-sentence. The findings are based on expert consensus and existing studies rather than new clinical trials. Actual efficacy in humans requires confirmation through rigorous clinical testing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.